Klotho to Acquire Turn Bio Assets in $300M Longevity Deal

Klotho Neurosciences, Inc. has announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc., a pioneer in cellular reprogramming and induced pluripotent stem cell (iPSC) technologies. The proposed deal, involving a mix of cash and stock, is still subject to due diligence and the signing of a definitive agreement, but if finalized, it would position Klotho as a major player in the emerging field of longevity therapeutics.

Through the LOI, Klotho would acquire Turn’s proprietary ERA (Epigenetic Reprogramming of Age) platform and its eTurna RNA delivery system. These technologies aim to reverse cellular aging and restore tissue function, with potential applications across a wide range of conditions—from dermatology and osteoarthritis to neurodegenerative diseases like ALS.

A key part of the deal includes the acquisition of an existing out-licensing and co-development partnership with a leading South Korean pharmaceutical company, valued at up to $300 million. The agreement signals strong commercial interest in Turn’s platform and its broader therapeutic potential.

“This LOI marks a transformative step for Klotho,” said Dr. Joseph Sinkule, CEO of Klotho Neurosciences. He noted that the addition of Turn’s RNA-based cellular rejuvenation technology represents a significant expansion of Klotho’s mission, moving beyond its original focus on the Klotho gene. The ERA platform utilizes six RNA molecules, including four of the well-known Yamanaka factors, to reset cellular age, while the eTurna delivery system uses lipid nanoparticles to effectively deliver these molecules into cells.

Klotho plans to rebrand following the completion of the transaction to reflect its broader focus and expanded therapeutic pipeline. The company also intends to integrate key members of Turn’s management and R&D teams.

With the global population aged 60 and older expected to reach 2.1 billion by 2050 and age-related healthcare costs projected to surpass $47 trillion by 2030, Klotho aims to lead the charge in developing therapies that address aging at the cellular level.